These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 29199764)

  • 1. Pharmacogenetics in psychiatry: Clinical case of resistant depression and a previous history of multiple adverse effects.
    Aguilar E; Monreal JA; Palao DJ
    Actas Esp Psiquiatr; 2017 Nov; 45(6):303-6. PubMed ID: 29199764
    [No Abstract]   [Full Text] [Related]  

  • 2. Gene expression and proliferation biomarkers for antidepressant treatment resistance.
    Breitfeld J; Scholl C; Steffens M; Laje G; Stingl JC
    Transl Psychiatry; 2017 Mar; 7(3):e1061. PubMed ID: 28291260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment-resistant depression and antidepressant plasma level: Proposal of a pharmacogenetic-integrative algorithm from a case report].
    Bourla A; Chaneac E; Ferreri F
    Encephale; 2019 Feb; 45(1):92-94. PubMed ID: 29887302
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment-resistant depression: a challenge for future research.
    Kasper S
    Acta Neuropsychiatr; 2014 Jun; 26(3):131-3. PubMed ID: 25279416
    [No Abstract]   [Full Text] [Related]  

  • 5. European Group for the Study of Resistant Depression (GSRD)--where have we gone so far: review of clinical and genetic findings.
    Schosser A; Serretti A; Souery D; Mendlewicz J; Zohar J; Montgomery S; Kasper S
    Eur Neuropsychopharmacol; 2012 Jul; 22(7):453-68. PubMed ID: 22464339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression.
    Kautzky A; Baldinger P; Souery D; Montgomery S; Mendlewicz J; Zohar J; Serretti A; Lanzenberger R; Kasper S
    Eur Neuropsychopharmacol; 2015 Apr; 25(4):441-53. PubMed ID: 25769916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Potential Case of Acute Ketamine Withdrawal: Clinical Implications for the Treatment of Refractory Depression.
    Roxas N; Ahuja C; Isom J; Wilkinson ST; Capurso N
    Am J Psychiatry; 2021 Jul; 178(7):588-591. PubMed ID: 34270337
    [No Abstract]   [Full Text] [Related]  

  • 8. Ketamine helps a third of patients with treatment resistant depression, finds small UK study.
    Torjesen I
    BMJ; 2014 Apr; 348():g2576. PubMed ID: 24699320
    [No Abstract]   [Full Text] [Related]  

  • 9. [MAO-inhibitors--a treatment option for treatment resistant depression: application, efficacy and characteristics].
    Köhler S; Stöver LA; Bschor T
    Fortschr Neurol Psychiatr; 2014 Apr; 82(4):228-36; quiz 237-8. PubMed ID: 24710679
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of the potassium channel gene KCNK2 in major depressive disorder.
    Congiu C; Minelli A; Bonvicini C; Bortolomasi M; Sartori R; Maj C; Scassellati C; Maina G; Trabucchi L; Segala M; Gennarelli M
    Psychiatry Res; 2015 Feb; 225(3):489-92. PubMed ID: 25535009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Family history of major depression and residual symptoms in responder and non-responder depressed patients.
    Serretti A; Chiesa A; Calati R; Sentissi O; Akimova E; Kasper S; Zohar J; De Ronchi D; Mendlewicz J; Amital D; Montgomery S; Souery D
    Compr Psychiatry; 2014 Jan; 55(1):51-5. PubMed ID: 24156872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated S-ketamine infusions in therapy resistant depression: a case series.
    Segmiller F; Rüther T; Linhardt A; Padberg F; Berger M; Pogarell O; Möller HJ; Kohler C; Schüle C
    J Clin Pharmacol; 2013 Sep; 53(9):996-8. PubMed ID: 23893490
    [No Abstract]   [Full Text] [Related]  

  • 13. Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.
    Fabbri C; Crisafulli C; Calati R; Albani D; Forloni G; Calabrò M; Martines R; Kasper S; Zohar J; Juven-Wetzler A; Souery D; Montgomery S; Mendlewicz J; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2017 Dec; 267(8):723-735. PubMed ID: 28260126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants: Are the Risks Worth the Benefits?
    Thase ME
    Psychiatr Clin North Am; 2016 Sep; 39(3):477-86. PubMed ID: 27514300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TNF-alpha inhibitor etanercept as monotherapy in treatment-resistant depression - report of two cases.
    Schmidt FM; Kirkby KC; Himmerich H
    Psychiatr Danub; 2014 Sep; 26(3):288-90. PubMed ID: 25191779
    [No Abstract]   [Full Text] [Related]  

  • 16. Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
    Wu Z; Chen J; Yuan C; Hong W; Peng D; Zhang C; Cao L; Fang Y
    J Affect Disord; 2013 Sep; 150(3):834-9. PubMed ID: 23570952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ketamine--a new treatment option for therapy-resistant depression].
    Köhler S; Betzler F
    Fortschr Neurol Psychiatr; 2015 Feb; 83(2):91-7. PubMed ID: 25723773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical and biological predictors of ketamine response in treatment-resistant major depression: Review].
    Romeo B; Choucha W; Fossati P; Rotge JY
    Encephale; 2017 Aug; 43(4):354-362. PubMed ID: 27623117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction: a fresh look at monoamine oxidase inhibitors for depression.
    Cohen LJ; Sclar DA
    J Clin Psychiatry; 2012; 73 Suppl 1():3-4. PubMed ID: 22951235
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravenous ketamine for treatment-resistant major depressive disorder.
    Covvey JR; Crawford AN; Lowe DK
    Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.